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Development of Quantitative Structure-
Pharmacokinetic Relationships
by Joachim M. Mayer* and Han van de Waterbeemd*t
Quantitative structure-activity relationships (QSAR) relating biological activity to physiochemical de-
scriptors have been successfully used foranumberofyears. It is also longrecognized that pharmacokinetic
parameters may play an important and even determinant role in drug action. This prompted several
researchers to focus attention to pharmacokinetic parameters as potential descriptors in quantitative drug
design. A number of examples of quantitative structure-pharmacokinetic relationships (QSPR) have ap-
peared in the literature.
The present contribution reviews some developments in this field. In particular, a number of concepts
and problems are critically discussed, rather than compilations of examples already published in recent
reviews. Attention will be paid to the main processes of the pharmacokinetic or toxicokinetic phase in
drug action, including absorption, distribution and elimination (biotransformation and excretion).
It is clear that quantitative approaches are ofconsiderable interest to toxicologists, since these methods
may contribute to the development of real predictive toxicology.
Introduction to Quantitative
Approaches
Since the stimulating work of Hansch (1,2) in the
beginning of the 1960s, it is clear that the biological
activity of chemical compounds can be related quanti-
tatively to their molecular structure. Initially, partition
coefficients (log P) have been studied extensively, and
this parameter still remains a descriptor of first choice
in QSAR work. Large compilations of partition coeffi-
cientsmeasuredinvarious solventsystems are available
(3-5). Many other physicochemical descriptors have been
evaluated for their potential use in correlation studies
between these descriptors and biological activity (4-7).
Application of computers (8-10) has made it possible to
evolve from qualitative (SAR) to quantitative (QSAR)
relationships. Although mainly developed by medicinal
chemists and used in the field of drug design, these
methods apply whenever organic compounds interact in
some way with living systems. The QSAR paradigm
therefore is ofinterest to all those working with drugs,
food additives, pesticides, biochemical reactants, envi-
ronmental pollutants and toxic products, since this
method provides a tool for the rational design of new
and safer drugs and chemicals (11,12). Although con-
siderable progress has been made, this ultimate dream
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has not yet become true. In the scope of the present
report we will only briefly discuss the QSAR approach.
A numberofgood introductions in this field canbe found
in the literature (3-7, 13-22). A complete answer to the
question on the real successes of QSAR in drug design
cannot be given. Most companies keep their secrets
carefully, sothatarealevaluation ofthemeritsofQSAR
is difficult (23). A nice example, however, is the success
story published by Cramer (24,25).
After the first decade of QSAR, around 1975, it be-
came clear that relationships derived from a series of
compoundsinvestigated inisolated systemsdonotapply
to in vivo situations. Time dependency of the concen-
tration course, i.e., the pharmacokinetics of the drug,
has been recognized to be one of the most important
factors for this discrepancy between the in vivo and in
vitro situation, and the influence of the factor time on
QSAR has been reported (14,26-28). Pharmacokinetics
of drugs has been studied for some time now (29-34)
and its importance in quantitative drug design fully ac-
cepted, since this subject was included in the program
of several recent QSAR symposia (22,36-39). A reason
interest has only recently been focused on quantitative
structure-pharmacokinetic relationships (QSPR) is the
lack of data obtained from homologous series of large
size. Pharmacokineticdescriptors aredependent onsex,
age, race, physical condition, etc. (35,36).
Excellent and recent reviews on quantitative struc-
ture-pharmacokinetic relationships have been pub-
lished (38,40-43), sowe focus ourattention onthe choiceMAYER AND VAN DE WATERBEEMD
FIGURE 1. Quantitative structure-pharmacokinetic relationships
(QSPR): a multidisciplinary effort.
and proper use ofpharmacokinetic parameters. Several
aspects of the present paper are collected in Figure 1.
The following types ofequations discussed in this paper
are (1) biological activity = f(physicochemical descrip-
tors) and (2) pharmacokinetic parameters = f (physi-
cochemical descriptors).
The first type ofequation corresponds to what is now
called QSAR, and which we may call QSTR when the
toxicity of a product is studied (44). It has also been
proposed to call this type of relationship QPAR (45),
quantitative physicochemical-activity relationships. The
second type of equation (2) is the topic of the present
paper and is abbreviated QSPR (38,42). This paper re-
views the use of pharmacokinetic parameters, as well
as their limitations, in QSPR. Toxicological and phar-
macological data can be handled in a similar way in
correlations between molecular structure and activity.
Therefore all quantitative methods discussed here, i.e.,
relationshipsbetweenstructure-activityandstructure-
pharmacokinetics, apply in fact for toxic products as
well, and deserve attention of toxicologists. In the fol-
lowing sections we will present first some definitions
and concepts and then develop the main processes of
the pharnacokinetic (or toxicokinetic) phase. These in-
clude absorption, distribution, metabolism and excre-
tion, the last two together referred to as elimination.
Foreach processitwillbeshownwhichpharmacokinetic
parameters can be obtained, and some of the actual
problems of the measurements and their potential ap-
plication will be discussed.
Some Concepts and Definitions
The established correlation between molecular struc-
ture and biological response as obtained fromthe QSAR
approach can be used in two ways. First, to predict the
molecularstructure producing an optimal response, and
second, to find elements allowing an understanding of
the mechanisms of action.
Acritical stepin QSAR is thedescriptionofmolecular
structure by appropriate physicochemical parameters.
As stated above, a large number of molecular descrip-
tors have been reported and evaluated. Among these
parameters, the partition coefficient (log P, describing
the lipophilic and hydrophilic properties) has allowed a
large quantity ofsuccessful correlations. The reason for
this is that distribution processes always, and binding
processes often, involve interactions with lipophilic bi-
ological environments, such as membranes and receptor
sites. Partition coefficients can be determined by the
classical shake-flask method. The solvent system most
frequently used is n-octanol/water for reasons exten-
sively discussed (46,47). Chromatographic methods
(HPLC, TLC) canalsobeused advantageouslytoobtain
lipophilic indices (48-50). Substituent constants Fr (2,4)
and fragmental constants f and f (3,4,51) have been
derived from experimental log P values. They allow,
with a certain number of corrections for special intra-
molecular influences, one to predict the hydrophobic
behavior of compounds. The shortcomings of these
methods have been reviewed by us (52). Recently an
attempt has been published to explain correction terms
used in current fragmental systems with a hydration
factor w (53).
The biological response can be a therapeutic one, i.e.,
desired, or a toxic one, undesired in the case of drugs,
desired in the development of insecticides or weedkill-
ers. When molecules produce therapeutic as well as toxic
effects, very precious information can be gained by in-
cluding both therapeutic and toxic responses in the
QSAR study. Indeed it isjudicious to select from aclass
the most selective, rather than necessarily the most
dose-potent member. The application of this approach
to the study ofpotential antitumor agents (54) has been
verypromising. Forinstance, thistype ofstudyallowed
Hansch and Hatheway (55) to recommend no further
work on triazenes as antitumor agents because the
structural features for toxicity could not be separated
from those of efficacy. The study of Quinn et al. (56)
showed the same tendency for 7- and 10-substituted
colchicines, potent mitoticinhibitors. Thatis, decreased
toxicity correlates with a simultaneous decrease in po-
tency. However, the same study revealed that the 4-
substituted compounds do not obey the correlation es-
tablished for the 7- and 10-substituted analogs, since
they show decreased toxicity for greater antitumor ac-
296QUANTITATIVE STRUCTURE-PHARMACOKINETIC RELATIONS
tivity. This implies thattheyhave abroader therapeutic
range. Although the 4-substituted compounds in this
series behave apparently as outliers, they finally made
it possible to uncover a promising new synthetic lead.
This illustrates that QSAR outliers are of particular
interest, a fact that should not be neglected.
The conclusions that can be drawn from a QSAR study
depend upon the biological model used. The information
content is the highest in biological systems ofhigh level
organization. However, this level is associated with a
high degree of biological complexity, making the ex-
traction ofthisinformation difficult. A current approach
is to step down to less complex biological systems. The
drawback ofsuch a procedure is the loss ofinformation
concerning the coordination of the processes involved
in the whole body being the ultimate target for drug
use. The complex sequence oftheprocesses determining
drug action can be segregated into three distinctive
phases: (1) pharmaceutical phase, (2) pharmacokinetic
phase, and (3) the pharmacodynamic phase.
The pharmaceutical phase (called exposure phase in
toxicology) comprises the factors determining the avail-
ability ofthe drug for absorption, e.g., solubility, com-
plex formation, chemical stability, influence ofexcipients,
etc. It should be kept in mind that these processes can
be rate-limiting and that false conclusions may result
when they are not taken into account (57-60).
The pharmacokinetic (ortoxicokinetic) phase includes
the processes of absorption, distribution, metabolism
and excretion. These processes modulate the concen-
tration-time profile ofthe substance at the receptor site
and consequently are important determinants of drug
action. Indeed, lack ofactivity may not be due to a low
affinityofthedrugforthereceptor, buttoaninadequate
concentration of the drug at these sites. The introduc-
tion ofphannacokinetic parameters accounting for a large
part ofthe complexity ofin vivo conditions should per-
mit one to interpret the structure-activity correlations
in physiological and biological terms. Some confusion
exists on the use of pharmacokinetic terms. Recently
Di Carlo (61) defined metabolism, biotransformation,
pharmacokinetics, and toxicokinetics as follows: (Xe-
nobiotic) metabolism is the sum of the processes af-
fecting the fate of a (foreign) substance in organisms,
including absorption, distribution, enzymatic and no-
nenzymatic reactions and excretion. Biotransformation
involves the chemistry of enzymatic and nonenzymatic
processes. Pharmacokinetics refers to the rate of met-
abolic processes. Toxicokinetics is used more restric-
tivelywhentoxicend-products areformed. Toillustrate
thatcertain definitions canbeuseddifferently, werecall
here that for Ariens, metabolic changes are included in
pharmacokinetics (29).
The pharmacodynamic (toxicodynamic) phase de-
scribes the interaction of the drug with its receptor or
otheractive sites and theresultingresponse. Thisphase
indrugaction can often be investigated in enzyme prep-
arations independently from the preceding phases. A
great number ofsuccessful QSAR correlations have been
obtained using enzyme preparations, i.e., a simple bi-
ological model. This type of QSAR has the limitations
mentioned above, that is a loss ofinformation compared
to a QSAR for the whole body.
There is no doubt that most pharmacokinetic param-
eters are strongly correlated with lipophilicity (log P).
However, one should be careful with the use ofcertain
pharmacokinetic parameters. A number of pitfalls and
difficulties will be highlighted in the next section.
Pharmacokinetic Parameters and
Their Potential Use in Quantitative
Structure-Pharmacokinetic
Relationships
Drug Absorption
The definition of the process of drug absorption is
more complex than it appears at a first glance. The
definition isdependentuponthecontextofexperimental
observation. In most cases this may lead to divergent
interpretations (32). Bythe mostappropriate definition,
absorption is the sum of processes by which a drug
proceeds from the site ofadministration to the site from
which the drug is transported to the site of action in
the body. The most studied routes ofabsorption are the
dermal (62) and the gastrointestinal route (63-65). The
possibilities and problems of percutaneous absorption
have been reviewed by Hadgraft (66). In the present
paper the discussion on absorption is based on the gas-
trointestinal route for which alarge body ofinvivo data
is available. In an in vivo situation, besides the already
mentioned limitation by the pharmaceutical phase, four
other rate-limiting steps can occur during absorption:
mucosaluptake, mucosalmetabolism, gastricemptying,
and blood flow.
Mucosaluptake andmetabolismcreatedifferencesbe-
tween luminal disappearance rates and blood appear-
ance rates (67,68). The results ofin situ techniques (69)
measuring disappearance rates should therefore be
checked for eventual mucosal interactions. Intestinal
drug absorption is more rapid than from the stomach.
The reason forthis is the greater surface area combined
with a more important blood irrigation of the intestine
as compared to that of the stomach. Gastric emptying
therefore is a controlling step of the rate of drug ab-
sorption (70,71). Thus the real influence oflipophilicity
onabsorption maybeblurredbygastricemptying. Once
the drug has passed the intestinal membrane, it is car-
ried away by the blood creating "sink conditions" which
assure continuous absorption. Highly lipophilic and small
polarcompounds penetrate sorapidlythroughthe mem-
brane that the draining effect ofblood flow becomes the
rate-limiting step for absorption (72). The decline ofthe
absorption rate forthe highermembers in ahomologous
series may therefore not be explained by simple par-
titionmodels (73), butby aphysiological limitation, e.g.,
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mesenteric blood flow. The drug must pass the liver
before reaching the systemic circulation. Indeed, vir-
tually all blood perfusing the gastrointestinal tissues
drains into the liver via the hepatic portal vein. The
loss of drug occurring during the first passage of the
gastrointestinal membranes andliveriscalledthe "first-
pass effect." If this phenomenon is not taken into con-
sideration, false QSAR analysis will result, particularly
if the metabolites produced are pharmacologically ac-
tive. The first-pass loss can be assessed by comparing
the pharmacokinetic data of oral administration with
those following intravenous dose in which an initial pas-
sage ofthe liver is avoided (74). Several methods allow-
ing one to differentiate between preabsorptive, gut
epithelial and hepatic first-pass biotransformation have
been described (75).
An important aspect in QSPR studies is the choice of
pharmacokinetic parameters for the description of a
physiological process. Some of the parameters are in-
tercorrelated in complex ways, making a nonambiguous
interpretation difficult. Absorption of a series of hom-
ologs described by the peak plasma level (Cmax) or the
area under the concentration-time curve (AUC) values
is often directly correlated with lipophilicity. The prob-
lems due to the use ofthese parameters have been rec-
ognized by Notari (76). Indeed, the direct comparison
of the blood level of chemical analogs fails to take into
account that these parameters are the complex result
of three pharmacokinetic phenomena. Besides absorp-
tion, they contain the process of distribution and elim-
ination [Eqs. (1)-(5)].
(1) c = FDka (e-kt ekat)
V(ka k)
FD = (Cl)(AUC)
Cl = kV
ln (kalk)
tmax t ka -k
(2)
(k/ka-k)
FD ka\
c ~~~~~~~~~~~(5)
Cmax V(k/
(klka k)
where C is the plasma drug concentration (amount/vol-
ume), k is the elimination rate, ka is the absorption rate,
F is fraction absorbed and D is dose thus FD is the
amount of drug in plasma; V is volume of distribution;
Cl is total plasma drug clearance, AUC is the surface
under the concentration-time profile; = tmax is the time
to obtain the maximal plasma drug concentration Cmax.
The symbols conform to those of Rowland and Tucker
(77).
For the same amount absorbed (FD) and identical
rate absorption (ka) the increase in Cmax can be due
either to a decrease of the volume of distribution (V),
the elimination rate constant (k) or a combination of
both. Consequently, only when V and k are constant,
will the change in Cmax represent a change in ka or F.
The separation of absorption and disposition (events
following the absorption process) is possible with de-
convolution procedures. The simplest of these proce-
dures, permitting assessment of the absorption rate
constant, is the graphical method known as the method
of residuals. More sophisticated techniques have been
reviewed by Cutler (78). Another frequently used, but
inappropriate, descriptor ofabsorption in QSAR/QSPR
is the percentage of drug absorbed (%abs). It can be
demonstrated that the relationship between %abs and
log P [Eq. 6] is not correct for extrapolation to high
lipophilicities, for which %abs becomes greater than
100%.
log (%abs) = a log P + b (6)
Seydel and Schaper (41) proposed for first-order absorp-
tion kinetics to transform %abs to ka by the expression
(7):
ka = -ln[1 -(%abs/100)]/t (7)
Other methods allowing one to determine ka without a
complete curve-fittinghave beencompiled byTucker(79).
Drug absorption has been extensively studied using
two- and three-compartment models. For the interested
reader we draw attention to a number of reviews (41-
43,80,81). Herewerepeat onlythatthesemodelsrevealed
a bilinear relationship between drug absorption (log ka)
and lipophilicity (log P) (80).
Protein Binding and Distribution
Plasma Protein Binding. Many drugs bind revers-
ibly to plasma proteins, among which mainly plasma al-
bumin, lipoproteins and glycoproteins are involved. The
extent of this binding has marked effects on the phar-
macokinetics andpharmacodynamics ofthe drug(82-84),
since in general only unbound drug can pass through
cellular membranes. The influence ofbinding on the pro-
cess ofdistribution, excretion and biotransformation will
be discussed below in more detail.
Albumin is the most abundant plasma protein and the
most important for plasma protein binding. Albumin binds
anionic as well as neutral compounds. Two different bind-
ing sites have been identified for albumin. It has been
shown (85) that drugs binding to site I, also called the
warfarin binding site, are generally bulky heterocyclic
molecules with a negative charge situated in the center
ofa largely lipophilic structure. Drugs, however, binding
to site II, the indole or benzodiazepine binding site, are
mainly molecules with an extended configuration carry-
ing at one extremity a negative charge away from the
nonpolarregion. Molecular structure determines binding
on two levels. First, the structure determines the site to
whichthecompound bindsandsecond influencesthe bind-
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ing within a given site. The relationship between molec-
ular structure and binding is difficult to establish when
within the studied series ofcompounds changes occur on
both levels. Therefore, most protein binding studies are
caried out with homologous series, i.e., compounds which
are variations ofthe same basic skeleton, where there is
little chance that the site ofbinding changes. The meth-
ods used to determine drug binding as well as the prob-
lems andpossibilities intheinterpretation ofbindingdata
have been extensively reviewed (41,42). A large number
of relationships between protein binding and molecular
structure have been published and recently compiled
(41,42). It is clear that lipophilicity is the most important
determinant of plasma protein binding. Other physico-
chemical parameters that have been identified to affect
protein binding are the electronic properties described
by pKa or Hammett (x values. In most cases, the rela-
tionship between the logarithms of the drug/protein as-
sociation constant Korthe ratio fraction bound to unbound
drug and log P is linear, i.e., an increase in lipophilicity
produces aproportionalincrease inbinding. Somestudies
reported parabolic relationships, the optimal logP vary-
ingconsiderably. This may indicate the influence ofstruc-
tural features. In a similar way, one can interpret the
fact that the linear relationship for different series of
homologs have approximately the same slope but very
different intercepts and cannot be combined into a single
regression line (86). The structural dependence ofprotein
binding becomes even more apparent when the modifi-
cation of lipophilicity at different sites of the basic skel-
eton produces different relationships with log P (86). In
conclusion, it can be said that protein binding depends
upon lipophilicity and molecular shape.
Volume ofDistribution. After absorption the drug
is distributed into body fluids and tissues. The extent
of distribution can be expressed by the volume of dis-
tribution. For drugs equilibrating rapidly throughout
the body after intravenous administration, the volume
ofdistribution can be detennined by dividing the amount
of drug in the body (dose D) by the initial plasma con-
centration (CO) obtained from extrapolation to time to.
Thevalueobtainedforthe volume (V = DICo), however,
has rarely the physiological meaning of an anatomic
space. Therefore, it is called the apparent volume of
distribution. This volume has to be considered as a pro-
portionality factor allowing one to calculate the amount
of drug in the body for a given plasma concentration.
It is not unusual that distribution is a time-dependent
process. The drug distributes in this case first into well
perfused tissues before poorly perfused regions. Con-
sequently, the volume of distribution is a function of
time and can be characterized in different ways.
When drug disposition (distribution and elimination)
can be described by a biexponential equation [Eq. (8)],
the distribution may be expressed bythe following terms:
the initial volume of distribution V1, the volume of dis-
tribution at pseudoequilibrium after bolus dose V, and
the volume of distribution at steady-state Vss. These
volumes and their calculation given by Eqs. (9)-(13).
C = Ce
' + Ce
12
V1 = D/(C1 + C2)
V = Cl/X2 = D/X2(AUC)
[(C1'/X2) (C21/A2)]
= l1 [(Cl'/X1) + (C2'/X2)]2
= Cl
1 (C1 + C2)
C2'=
C2
(C1 + C2)
(8)
(9)
(10)
(11)
(12)
(13)
Al and '2 are composed functions ofrate constants; the
rank-order ofmagnitudes in the volumes ofdistribution
is V1 < Vss < V.
The question arises which of these volumes is the
most appropriate for QSPR studies. V, does not de-
scribe the entire distribution process, while V is influ-
enced by elimination and tends therefore to overestimate
the extent of drug distribution. In contrast, Vss is not
affectedbychangesindrugelimination, reflectsthetrue
distribution volume, and hence should be used in QSPR
whenever possible.
The volume ofdistribution is dependent upon, among
other factors, the degree ofbinding to plasma proteins
f, and tissuesfuR. A quantitative interpretation of this
dependency is possible with the physiological distribu-
tionmodel developed by 0ie and Tozer(87), which takes
into account the presence ofproteins within and outside
the plasma. In this model the space in which the drug
distributes is divided into three physiological volumes:
the plasma VP the extracellular fluid outside the blood
plasma VE, and the remainder of the total body water
VR. Using the principles of mass balance, Eq. (14) was
obtained:
VSS = VP(1 + RE/I) +
fUVp[(Ve/VP) - RE/I] + VR(fJ/fuR) (14)
where RE/I is the ratio of the amount of protein in ex-
tracellular fluids to that in blood plasma. As demon-
strated above,fu is related to lipophilicity. In order to
separate the effect of lipophilicity on distribution from
that on plasma protein binding, the unbound volume of
distribution (Vss/fu) is often used. Figure 2, based on
Eq. (14), shows that Vss/fu is not completely independ-
ent ofplasma protein binding and increases sharply for
high binding (fu < 0.2). It can also be noted that the
relative increase in unbound volume is dependent upon
the degree of tissue binding. Indeed, in the absence of
tissue binding (fUR = 1), the change fromf, = 1 tofu
= 0.1 corresponds to an increase of 150% in the ratio
VSss/u. On the contrary, for drugs highly bound to tis-
sues (fUR = 0.1) the same change in fu increases the
unbound volume onlyby 23%. Therelationship between
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FIGURE 2. Relationship between unbound volume (Vss/f,,) and frac-
tion unbound (fu) based on Eq. (14), whereby, according to 0ie
and Tozer (87) it is assumed that Vp, VE, and VR are 3, 12, and 27
L, respectively, and that RE/I = 1.4.
plasma protein binding and tissue binding cannot be
predicted a priori. Changes in f, are not necessarily
accompanied by a similar change infuR- In the case of
nonspecific binding, depending only on lipophilicity,
however,fuandfuR are proportional. Consequently, the
effect offu is counterbalanced byfuR and the unbound
volume becomes more or less independent fromfu. The
unbound volume at steady state is therefore in most
cases an appropriate parameter to describe the effect
of variations in lipophilicity and distribution within a
series of homologs.
Most studies on this subject report a linear relation-
ship between the logarithms ofapparent volume ofdis-
tribution and partition coefficients in homologous series
ofcompounds (41,42,88). However, studies using series
ofcompounds and covering a very large range oflog P
values reveal a nonlinear behavior (89). In the range of
low log P values, log(Vssl/f) increases slowly. For high
log P values, on the contrary, important changes in log
(Vss/fu) are observed. Figure 3 illustrates this complex
relationship between unbound volume (Vss) and lipo-
philicity (log P) for a series of 5-alkyl-5-ethylbarbituric
acids. The model developed by Watanabe and Kozaki
(90) permits a rationalization of this phenomenon. The
drug distribution at pseudo-equilibrium is modeled by
three compartments (plasma space Vp, lipid space V1,
.6.
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FIGURE 3. Plot of unbound volume of distribution at steady-state
(V~slfj) in therat againstlipophilicity(logP) ofahomologousseries
of 5-n-alkyl-5-ethyl barbituric acids (89).
and nonlipid space V2) and two equilibrium constants k,
and k2, relating the concentration in V1 and V2, respec-
tively, to that in VP. Using the definition ofthe volume
of distribution as the ratio of the sum of the amounts
in the three compartments and the concentration in Vp,
the following equation was obtained:
V = Vp [1 + ki (V1/Vp) + k2(V2/VP)] (15)
Introducingalinearlog-logrelationship ofthe Collander
type between k and the partition coefficient P and
grouping the constants, this equation simplifies to (41):
log V = log (a + bPc) (16)
which clearly shows that the reported linear relation-
ships are special cases ofthe moregeneralequation (16),
thelinearrelationships beingsimplytheascendingpart.
Drug Elimination
The residence of the drug in the body is terminated
by elimination (biotransformation and excretion), the
rate of which is characterized by the elimination half-
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life(t,l2). The lattercan generally betaken directly from
the log(concentration)-time profile. The elimination half-
life has often been used to relate elimination to molec-
ular structure. This application, however, is disputable
because the half-life of a drug depends on two other
generally independent processes, namely distribution
and elimination. This can be seen in Eq. (17):
t12= ln 2(V/Cl) (17)
where V is the volume of distribution and Cl the total
body clearance. Clearance, in contrast, relates the rate
ofelimination to the plasma concentration and is a pure
descriptor of elimination (91). The total body clearance
can be determined from the dose absorbed (FD) and
total area under the drug concentration-time curve
(AUC) [Eq. (2)]. Different organs are responsible for
the elimination ofdrug from the body, the contribution
of the liver and kidney being the most important. The
total body clearance can therefore be regarded as the
sum of the individual organ clearances. If drug elimi-
nation is restricted to renal excretion (CIR) and hepatic
metabolism (ClH), the total clearance is described by
Eq. (18).
Cl = CIR + CIH (18)
In addition to plasma data, allowing the determination
ofthe total clearance, when urine data are available for
the estimation ofClR, both processes ofelimination can
be assessed separately. The methods and problems of
the measurement ofrenal clearance have beendiscussed
by Tucker (92). Based on mass-balance considerations
clearance of an individual organ can be expressed by:
Cl = QE (19)
where Q is the blood-flow through the eliminating organ
and E is the extraction ratio of the drug. The value of
E lies between zero, when no drug is eliminated, and
unity, when the drug is completely removed by the
organ. One can rationalize from Eq. (19) that clearance
becomes limited by blood flow for highly cleared drugs.
Adeeperunderstanding ofthe influence ofphysiological
parameters (e.g., blood flow, protein binding and in-
herent ability ofthe organ to extract the drug) on organ
clearance can be gained considering the well-stirred
model of hepatic clearance (93,94):
Cl = QfubCluint (20)
fubClu,int + Q (0
In this equationfub is the fraction of unbound drug in
the blood and Clu,int is the intrinsic clearance ofunbound
drug. With Eq. (20) two extreme situations can be il-
lustrated. First, if the extraction by the organ is very
efficient, thenfubClu,int > Q, and the organ clearance
becomesindependent ofbinding and equaltoblood flow.
This condition can be reached by highly lipophilic mem-
bers within acongeneric series and has the consequence
thatanyfurtherincreaseinlipophilicity will notproduce
anincrease ofclearance beyond the limitingorgan blood
flow. In the opposite extreme situation, the organ is
veryinefficient atremovingthe drug. ThenfUbClU,int <<
Q, and organ clearance reduces to:
Cl = fubClu,i,t (21)
In this case the rate-limiting step is not the blood flow
but the organ's intrinsic capacity to eliminate the drug,
and clearance becomes dependent on the fraction ofun-
bound drug in the blood. In practice, most drugs fall
between these two extremes. Rational QSPR studies
should therefore use the intrinsic clearance, which is
independent of binding and blood flow, as an index of
enzymatic activity. When certain conditions are satis-
fied the intrinsic clearance can be determined from the
dose D and the area under the concentration-time pro-
file (AUC) after oral administration. The first condition
is that no extrahepatic clearance is involved, the second
is that intestinal absorption is complete. In this case F
is equal to (1 - E), where E is the fraction of drug
removed by the liver. Consequently, F is the fraction
of drug that reaches the systematic circulation and can
be expressed by Eq. (22).
F = Q
(Q + fubClU,int)
(22)
Combining Eq. (20) and (22) shows thatunderthe above
mentioned circumstances the oral clearance (Cl0) is equal
to the unbound intrinsic hepatic clearance [Eq. (23)].
Clo = Do/AUCo
= Cl/(l - E)
= Cl/F
= fubClu,i,t
(23)
However, the restrictions permitting one to establish
the above relationship are rarely met. The condition to
determine Clu, int is therefore the knowledge of binding
and blood flow. However, blood flow can be submitted
to important inter- and intraindividual variations and
its exact assessment in the whole body is difficult. Ifan
investigation of the influence of blood flow and binding
is desired the use of isolated perfused liver becomes
necessary.
Biotransformation of drugs produces very often sev-
eral metabolites by different pathways. Generally, the
dependency onlipophilicity ofmetabolite formation var-
ies (95-97). A clearer picture can be obtained when the
individual metabolite clearances are determined and
correlated separately with log P.
Renal excretion is the net result of the processes of
filtration, reabsorption, and secretion. Any interpre-
tation of renal clearance data, which can be measured
directly (92), requires, therefore, the consideration of
the different components. For drugs that are only fil-
tered, the renal clearance (ClR) is equal to the product
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FIGURE 4. Model expressing the urine flow dependence of reab-
sorption. Assumptions: each nephron acts as single functional unit;
proximal, distal and collecting tubule have the same reabsorption
characteristics; drug is nondissociated and not secreted; P, =
permeability constant of water; PD = permeability constant of
drug. Then the rate ofchange ofluminal fluid volume is - P,, the
rate of change of luminal drug concentration is - PD(CU - f,u C,,),
and
IT (GFR - Qu,,) - 11
QU,,,) - IT
where wr, defined by the product of the permeability constant of
the drug and the tubular surface, is an expression of the tubular
permeability for a given compound (99).
of the fraction unbound to plasma protein (fJ) and the
glomular filtration rate (GFR):
CIR = fUGFR (24)
Note that only unbound drug is available for filtration.
Corrected for the influence of lipophilicity on binding,
the unbound renal clearance (CIR/fU) ofonly filtered drugs
is independent oflipophilicity and conforms to the value
of GFR. Toon and Rowland (98) have shown that this
analysis applies to a series of tetracyclines. When the
unbound clearance is greater than GFR, secretion must
be involved besides filtration. The dependence of se-
cretion upon blood flow and binding is similar to that of
hepatic clearance discussed above and expressed in Eq.
(20). The renal clearance of drugs with low secretion
depends on binding and not on blood flow, whereas for
high secretion the inverse can be observed. Reabsorp-
tion is amajor factor ofrenal handling. Drug must have
been reabsorbed when the unbound renal clearance is
smaller than GFR. Reabsorption can be a passive or
active process. The latter mechanism is predominant in
the reabsorption of vitamins and endogenous com-
pounds, such as electrolytes, amino acids and glucose.
URINE FLOW (p1/min)
FIGURE 5. Simulation ofthe effect ofpermeability on the urine flow
dependence of the urine-to-perfusate concentration ratio by use
of the expression for C...JC,p of Fig. 4. For the simulation f, = 1
and GFR = 1 mL/min (99).
The vast majority of drugs are reabsorbed passively,
the driving force being the concentration gradient be-
tween tubular lumen and plasma created by the renal
reabsorption of water. Consequently, the passive dif-
fusion ofthe drug across the tubular membrane reaches
its upper limit when the concentration in the urine Cu
becomes equal to the unbound concentration in the
plasma Cp. The magnitude ofreabsorption ofdrugs de-
pends not only upon physicochemical characteristics of
the substance, e.g., its lipophilicity and degree of ion-
ization, but also upon physiological variables such as
extent of reabsorption of water, urine flow, filtration
rate and urine pH.
The dependence ofrenal clearance on urine flow, glo-
merular filtration rate and fraction unbound can be ex-
plained by a simple physiologically based model (99).
The assumptions allowing the elaboration ofthis model
are recapitulated in Figure 4. The model predicts for
drugs for which the tubular membranes are imperme-
able (,rr = 0), that the ratio CJCP depends on the ratio
GFR/Qur times fu. Consequently, for high urine flow
rates (Qu), approaching GFR, the ration Cul/Cp gets close
tofu. For low urine flow, e.g., when 99% of water is
reabsorbed, the ratio Cu/CP is independent ofthe prod-
uctfUGFR. If the tubular is highly permeable (,T = mo)
for the drug, reabsorption rapidly reaches equilibrium
z
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andthentheratioCJiCPisgivenbyfuandisindependent
of urine flow. Figure 5 illustrates in addition to these
two extremes the influence of intermediate values of
tubular permeability on the reabsorption of unbound
drug, assuming a value of 1 mL/min for GFR and fu
equal to 1. A study of the tubular reabsorption of a
homologous series ofbarbituric acids in an isolated per-
fused rat kidney preparation applies this model (99). It
was shown that a linear relationship exists up to equi-
librium condition between log P and the permeability
constant m. The decisive advantage of this model over
simple correlations between renal clearance and lipo-
philicity is its ability to take into account the changes
in fraction of drug unbound, glomerular filtration rate
and urine flow, which are the major determinants of
renal excretion of filtered and reabsorbed drugs.
Urine pH is anotherimportant factorofreabsorption.
Indeed, only nonionized and sufficiently lipophilic com-
pounds are passively reabsorbed, whereas in general
ionized compounds are not. Consequently, the renal
clearance of weak acids and bases can be altered con-
siderably when tubular reabsorption is pH-sensitive.
This is the case for acids whose pKa value lies between
3.5 and 7.5 and for bases with pKa values between 7
and 11. Only a limited number of correlations between
drug elimination and molecular structure have been
published (41,42). Considering the complex physiolog-
ical situation discussed above, it appears that the choice
of biological parameter is crucial for successful corre-
lations. Pharmacokinetic descriptors which are the com-
bination ofseveral basic parameters are called secondary
parameters. TheycanonlybeusedsuccessfullyinQSPR
when one ofthe included parameters changes more rap-
idly with lipophilicity than do the others. Primary pa-
rameters, describing only one pharmacokinetic feature,
should preferentially be used. Note that the fraction (or
percent) of drug excreted unchangedfe, often used to
describe renal clearance, is in fact dependent on non-
renal clearance, as can be shown by equation (25).
total drug excreted unchanged
fe- =dose
rate of excretion
rate of elimination (25)
- CIR/Cl
Predictive Toxicology, Another
Dream?
In the previous section an overview was given ofthe
possible use of pharmacokinetic parameters in quanti-
tative drug design. As already stated in the introduc-
tion, quantitative methods, such as QSAR and QSPR,
apply as well for toxicological problems in which we are
interested in particular in the present context. We are
aware ofthe fact that this review is far from complete.
Therefore the interested reader is referred to the cited
literature. In the rest ofthis section some remarks will
be made on the possibilities for using metabolic, i.e.,
pharmacokinetic and biotransformation, information in
predictive toxicology. In other words: is it possible to
predict toxicity from molecular structure?
Toxicity is a relative term, since, e.g., pesticides and
weed-killers should betoxic forone species and nontoxic
for others. The principle ofselectivity (100) also applies
for different tissues within a species and therefore is of
great importance for the development of anticancer
drugs. A successful application of a quantitative struc-
ture-selectivity relationship (QSSR) has been reported
for drugs with potential use in cancer therapy (1). In-
terest in the prediction oftoxic activity isgrowing (101-
105). A predictive structure-activity model for chemi-
cals that have not yet been subjected to carcinogenesis
assays has recently been reported (106). In that partic-
ular study the products were directly toxic. In other
situations bioactivation yields toxic metabolites. There-
fore a thorough understanding ofthe fate ofa chemical
in a living system, i.e. a detailed knowledge ofbiotrans-
formation (107-111), is a prerequisite in predictive tox-
icology. The regulation ofbiotransformation is a recent
and important new tool to avoid toxic products. Two
concepts, not discussed here, namely the concepts of
prodrugs (112) and "soft" drugs (113), both aimed at a
better control of the fate of the drug in the body, are
promising and already have proven their applicability.
Metabolic routes and pharmacokinetic characteristics
can be influenced by the introduction of D,F or CH3 at
certain critical positions inthe drugmolecule. However,
it should not be forgotten that these manipulations may
also involve possible changes of physicochemical prop-
erties such as lipophilicity (114,115). Ariens (21) re-
marked at a recent symposium summing-up, that
examples of quantitative structure-biotransformation
relationships are completely lacking. However, like for
QSPR, more and more examples have been reported
recently (95,97,116-119). Several efforts are under-
taken to design computer programs that are able to
predict metabolic products (120). These products in turn,
ifalready known, can be compared with compilations of
toxicity data. Potential toxicity can thus be detected in
an early stage, and thus suspect functional groups
avoided. Clearly, the computer is and will be an im-
portant tool forthe toxicologist as itbecame inthe 1970s
for the medicinal chemist (8-10).
Conclusions
In this paper we have used models to describe the
complex interdependency of pharmacokinetic parame-
ters. Physiologically based pharmacokinetic modeling
(121) is a step further to total modeling, describing the
whole body by a number of anatomical compartments.
In a more general way, simultaneous modeling of the
pharmacokinetic and pharmacodynamic phases of drug
actionhasbeenreported (122). Ifwewanttounderstand
thereallimitingfactorsindrugactioninthewholebody,
astepwise multiple QSAR(MUQSAR)technique should
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be considered. That is, each step in drug action should
be analyzed by using a quantitative method, thus per-
mitting one to fully conceive an overall QSAR. Math-
ematically this approach can be written as:
overall QSAR =
J(QSARi, QSPRj, QSBRk, QSTR1,) (26)
where i,j,k and I = 1, . . ., n. QSBR and QSTR stand
forquantitative structure-biotransformation and struc-
ture-toxicity relationships, respectively. This approach
is rather time-consuming, and certain practical prob-
lems have to be tackled. However, it is our belief that
the information finally obtained is worth the effort.
There is little doubt that the introduction of phar-
macokinetic parameters in QSAR is a step towards a
more rational drug design, that is in the development
of drugs and chemicals with an optimal wanted effect
and a certain acceptable toxicity-profile, both predicted
and understood. As shown in this paper, pharmacoki-
netic parameters can be useful, but only when used
properly.
The authors thank Prof. Bernard Testa for fruitful discussions and
for drawing their attention to a number of references used in this
review.
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